Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-04-09
2011-10-04
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S202000
Reexamination Certificate
active
08030330
ABSTRACT:
This invention provides compounds of formula Iand pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range.The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4391755 (1983-07-01), Wang et al.
patent: 4418068 (1983-11-01), Jones
patent: 4515805 (1985-05-01), Newman
patent: 4605517 (1986-08-01), Riley et al.
patent: 4988710 (1991-01-01), Olney
patent: 5202129 (1993-04-01), Samejima et al.
patent: 5441964 (1995-08-01), Bryant et al.
patent: 5464845 (1995-11-01), Black
patent: 5464853 (1995-11-01), Chan
patent: 5478847 (1995-12-01), Draper
patent: 5494920 (1996-02-01), Glasebrook et al.
patent: 5494929 (1996-02-01), Grese
patent: 5532254 (1996-07-01), Bowling
patent: 5629425 (1997-05-01), Labell et al.
patent: 5731327 (1998-03-01), Luke
patent: 5811120 (1998-09-01), Gibson et al.
patent: 6303634 (2001-10-01), Cohen et al.
patent: 6458811 (2002-10-01), Arbuthnot et al.
patent: 6797719 (2004-09-01), Arbuthnot et al.
patent: 6894064 (2005-05-01), Arbuthnot et al.
patent: 6906086 (2005-06-01), Black
patent: RE38968 (2006-02-01), Black et al.
patent: RE39050 (2006-03-01), Draper et al.
patent: 2004/0167170 (2004-08-01), Cohen
patent: 2141999 (1995-09-01), None
patent: 2158399 (1995-09-01), None
patent: 108606 (1983-11-01), None
patent: 605193 (1993-12-01), None
patent: 670162 (1995-02-01), None
patent: 674903 (1995-10-01), None
patent: 0683170 (1995-11-01), None
patent: 2097788 (1982-11-01), None
patent: 2293382 (1996-03-01), None
patent: 95/17382 (1995-06-01), None
Exhibit I. NCI “what is prevention” Web printout p. 1-2 (2008).
Exhibit II NCI “cancer prevention overview” Web printout p. 1-4 (2008).
Exhibit III. NCI “Clinial trial results—tamoxefen approved for ductal breast cancer” Web printout p. 1-3 (2008).
Levine “Tamoxifen and . . . ” BMC Cancer4.49. pp. 1-8 (2004).
Parikh et al. “Prevention of . . . ” Clin. Cancer Res. 11(23) p. 8512-8520 (2005).
Mayo definition of menopause (2010).
Lieberman, et al., “Pharmaceutical Dosage Forms” Marcel Dekker, Inc., pp. 107-117, 186-187, 1980.
Omelczk, et al., “Influence of micronizafion on the compacton properties of an investigational drug using tableting index analysis”, Eur. J. Pharnm Biopharm., vol. 43, 95-1 oc., 1997.
Jones, J. Med Chem., 27:1057-1066, 1984.
Pharmaceutics, Chief Editor: Mr. XiNiao Zhu, the People's Health Publishers, Third Edition, Jul. 1994.
Bowman, W.C., et al, Blackwell Scientific Publications, Textbook of Pharmacology, Second Edition, pp. 40.9, 1980.
Livingston, Churchill “Pharmaceutics: The Science of Dosage Form Design”, New York, NY, Chapters I and 13, 1988.
Remington's Pharmaceutical Sciences, Igm Ed., Mack Publishing Company, Eaton, PA, Chapters 19, 31 and 89, 1990.
Barr Laboratories, Inc., Oct. 1, 2004 Paragraph IV Certification Letter to Eli Lilly and Company re: US Patent No. 6,797,719.
Webster's II New Riverside University Dictionary p. 933 (1976).
Byers, T. “What can randomized controlled trials tell us about nutrition and cancer prevention?” CA Can. J. Glin. v.49 (6) p. 353-361 (1999).
Levine, L., “Tamoxifen and the Rafoxifene analog LY117018: their effects on arachidonic acid release from cells in culture and on prostaglandin I2 production by rat liver cells” BMC Cancer 4(49) pp. 1-8 (2004).
Parikh, R. R. et al. “Prevention of N-Methyl-N-Nitrosourea-lnduced Breast Cancer by alpha-Fetoprotein (AFP)-Derived Peptide, a Peptide Derived from the Active Site of AFP”, Clin. Cancer Res. 11(23) p. 8512-8520 (2005).
Azaroff, L. V., The powder method in x-ray crystallography, pp. 254-258, McGraw-Hill Book Company, Inc. (1958).
JJSHP vol. 24, No. 11, p. 1175-1182 (1988)—Japanese Journal for History of Pharmacy.
Nakagawa, H., Formulation of poorly-soluble drugs, JJSHP vol. 24, No. 11, p. 1175-1182 (1988)—English translation of JJSHP vol. 24, No. 11 (1988).
Eli Lilly and Companyvs.Teva Pharmaceuticals, Inc., Case 1:06-cv-01017-SEB-JMS, U.S. District Court Southern District of Indiana, Sep. 23, 2009.
Webster's II New Riverside University Dictionary, (1984) p. 286.
Nystrom et al., “Comparison of permeametry and photometry for the measurement of surface area of powders”, (1978), CA 88:126272.
Lieberman et al., “Pharmaceutical Dosage Forms” vol. 2, Marcel Dekker, (1989) p. 453.
Judgment, dated Sep. 1, 2010, United States Court of Appeals for the Federal Circuit,Eli Lilly and Company, Plaintiff-Cross Appellant v.Teva Pharmaceuticals USA, Inc., Defendant-Appellant, Case No. 06-CV-1017.
Arbuthnot Gordon Nelson
Dalder Brian Weston
Hartauer Kerry John
Luke Wayne Douglas
Stratford, Jr. Robert Eugene
Birch Gary M.
Chang Celia
Eli Lilly and Company
LandOfFree
Benzothiophenes, formulations containing same, and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzothiophenes, formulations containing same, and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiophenes, formulations containing same, and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4275783